Clinically, the use of PDE5 inhibitors in type 2 diabetes mellitus (T2DM) is associated with a lower risk of overall morbidity and mortality in those with a history of acute MI (316). This evidence concerns the gene PDE5A and type 2 diabetes mellitus.